ArticleDrug delivery2019
Novel ultra-small micelles based on ginsenoside Rb1: a potential nanoplatform for ocular drug delivery.
Article in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- A safe and anti-inflammatory plant-derived nanovesicle platform for targeted delivery in acute lung injury.Bioactive materials · 2026Article
- Advanced herbal self-assembled nanoplatforms: targeted, stimuli-responsive, and precision therapeutics for human diseases.Journal of nanobiotechnology · 2026Review
- Research progress on self-assembled supramolecular bioactive materials from herbal natural products and their applications in anti-infection field.Materials today. Bio · 2026Review
- The Perspectives of Combining Antibiotics with Saponins-Herbal Excipients.Molecules (Basel, Switzerland) · 2025Review
- Immuno-protective cationic ginsenoside Rb1 vesicles for macrophage-mediated targeted therapy of inflammatory diseases.Materials today. Bio · 2025Article
- Topical Ocular Drug Delivery: The Impact of Permeation Enhancers.Pharmaceutics · 2025Review
- Drug self-delivery systems: A comprehensive review on small molecule nanodrugs.BioImpacts : BI · 2025Review
- Envisioning the Future: Nanomicelles Revolutionizing Ocular Drug Delivery.Pharmaceutical nanotechnology · 2025Review
- Preparation and characterization of micellar nanoparticles using crude saponins from five Congolese plant species.Pharmaceutical science advances · 2024Article
- Natural Products from Herbal Medicine Self-Assemble into Advanced Bioactive Materials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Smart nanoparticles for cancer therapy.Signal transduction and targeted therapy · 2023Review
- Dendrimer and dendrimer gel-derived drug delivery systems: Breaking bottlenecks of topical administration of glaucoma medications.MedComm - biomaterials and applications · 2023Article
- Ginseng Saponin Rb1 Attenuates Cigarette Smoke Exposure-Induced Inflammation, Apoptosis and Oxidative Stress via Activating Nrf2 and Inhibiting NF-κB Signaling Pathways.International journal of chronic obstructive pulmonary disease · 2023Article
- Design of ophthalmic micelles loaded with diclofenac sodium: effect of chitosan and temperature on the block-copolymer micellization behaviour.Drug delivery and translational research · 2022Article
- Ubisol-QAntioxidants (Basel, Switzerland) · 2021Review
- Potential Herb-Drug Interactions in the Management of Age-Related Cognitive Dysfunction.Pharmaceutics · 2021Review
- The Effects of Ginsenosides on the Nrf2 Signaling Pathway.Advances in experimental medicine and biology · 2021Article
- Therapies Based on Nanoparticles for Eye Drug Delivery.Ophthalmology and therapy · 2020Review
- Preparation and study of two kinds of ophthalmic nano-preparations of everolimus.Drug delivery · 2019Article
- Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective.Recent patents on drug delivery & formulation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesGinsenosides Rb1 (Rb1) could form micelles in aqueous solutions. Self-assembled Rb1 micelles could potentially be utilized as ocular drug delivery system, and it was postulated that the encapsulation of a medicine within Rb1 micelles might strengthen the drug's therapeutic action and reduce side effects.
methodsDiclofenac-loaded Rb1 micelles (Rb1-Dic micelles) were formulated, optimized, and then further evaluated for in vitro cytotoxicity/in vivo ocular irritation, in vivo corneal permeation, and in vivo anti-inflammatory efficacy.
resultsRb1 self-assembled into micelles with ultra-small particle size (<8 nm) in a homogeneous distribution state (polydispersity index [PDI] < 0.3). Diclofenac was highly encapsulated into the micelles according to the weight ratios of Rb1 to diclofenac. The ophthalmic solution of Rb1-Dic micelle was simple to prepare. Rb1 had good cellular tolerance, and it also improved the cellular tolerance of the encapsulated diclofenac. Rb1-Dic micelles also showed non-irritants to the rabbit eyes. The use of Rb1 micelles significantly improved the in vivo corneal permeation as well as the anti-inflammatory efficacy of diclofenac when compared to commercial diclofenac eye drops.
conclusionRb1 micelle formulations have great potential as a novel ocular drug delivery system to improve the bioavailability of drugs such as diclofenac.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.